1. Economic Analysis of National Program for Hepatitis C Elimination, Israel, 2023
- Author
-
Yuval Dadon, Francis B. Mimouni, Ariella Toren, Tal Morgenstern, Lior Barak, and Joseph Mendlovic
- Subjects
Hepatitis C ,viruses ,elimination program ,cost estimation ,Israel ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
In 2021, the Israel Ministry of Health began a national hepatitis C elimination program. Implementing a World Health Organization goal, Israel’s program involved targeted screening, barrier minimization, workup simplification, awareness campaigns, and a patient registry. We evaluated program costs for testing and treatment. By May 15, 2023, the program had identified 865,382 at-risk persons, of whom 555,083 (64.3%) were serologically screened for hepatitis C virus (HCV), which was detected in 24,361 (4.4%). Among 20,928 serologically positive patients, viremia was detected in 13,379 (63.9%), of whom 10,711 (80%) were treated, and 4,618 (96.5%) of 4,786 persons receiving posttreatment HCV RNA testing had sustained virologic response. We estimated costs of ₪14,426 (new Israel shekel; ≈$3,606 USD) per person whose HCV infection was diagnosed and successfully treated. The program yielded screening and treatment in almost two thirds of the identified at-risk population. Although not eliminated, HCV prevalence will likely decrease substantially by the 2030 target.
- Published
- 2024
- Full Text
- View/download PDF